Investing.com – U.S. stocks were higher after the close on Friday, as gains in the Industrials, Basic Materials and Technology sectors led shares higher. At the close in NYSE, the...
Investing.com – U.S. stocks were lower after the close on Wednesday, as losses in the Healthcare, Oil & Gas and Industrials sectors led shares lower. At the close in NYSE, the Dow...
Gainers: Nemaura Medical (NASDAQ:NMRD) +29%. Proteostasis Therapeutics (NASDAQ:PTI) +19%. Replimune Group (NASDAQ:REPL) +18%. NuVasive (NASDAQ:NUVA) +16%. OHR Pharmaceutical...
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced that it has received a notice for the termination of the global license and collaboration agreement for developing...
Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) , announced it plans to amend the ongoing MAKO Study evaluating Squalamine (also known as OHR-102) in wet form of age-related macular...
As of late, it has definitely been a great time to be an investor in OHR Pharmaceutical Inc (NASDAQ:OHRP) . The stock has moved higher by 25% in the past month, while it is also...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Sell | Buy | Sell | Strong Sell |
| Technical Indicators | Strong Sell | Sell | Buy | Sell | Strong Sell |
| Summary | Strong Sell | Sell | Buy | Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 148.79 | 148.97 | 147.22 | -0.24 | -0.16% | 67.85M | NASDAQ | |||
| 373.06 | 373.56 | 369.71 | -0.86 | -0.23% | 11.57M | NASDAQ | |||
| 2,872.20 | 2,886.00 | 2,848.00 | -16.4 | -0.57% | 1.28M | NASDAQ | |||
| 34.30 | 35.57 | 33.73 | -2.44 | -6.64% | 35.51M | NYSE | |||
| 19.37 | 19.90 | 19.12 | -0.61 | -3.05% | 9.11M | NYSE | |||
| 221.03 | 229.22 | 219.95 | -7.67 | -3.35% | 1.42M | NYSE | |||
| 22.47 | 22.65 | 21.85 | +0.52 | +2.37% | 2.65M | NASDAQ | |||
| 565.13 | 567.81 | 555.80 | +13.46 | +2.44% | 548.11K | NASDAQ | |||
| 149.18 | 153.30 | 147.49 | -5.09 | -3.30% | 1.34M | NYSE | |||
| 55.43 | 56.98 | 54.87 | -2.28 | -3.95% | 8.12M | NYSE | |||
| 77.61 | 80.00 | 76.65 | -2.51 | -3.13% | 1.67M | NYSE | |||
| 440.65 | 446.64 | 429.00 | +6.19 | +1.42% | 10.07M | NASDAQ | |||
| 57.33 | 58.82 | 57.13 | -0.23 | -0.40% | 23.82M | NASDAQ | |||
| 97.32 | 98.59 | 96.91 | -0.92 | -0.94% | 10.41M | NYSE | |||
| 44.47 | 44.99 | 44.03 | -0.30 | -0.67% | 22.12M | NYSE |
NeuBase Therapeutics, Inc. is a pre-clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat rare genetic diseases and cancers caused by mutant genes. The Company’s peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the HD messenger ribonucleic acid (mRNA) and NT0200, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the myotonic dystrophy type one disease mRNA.